Side-by-side · Research reference
LiraglutidevsTestagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedFlagship14/45 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
Liraglutide
Testagen
Primary target
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
Testicular tissue; proposed nuclear DNA interaction
Pathway
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
Unknown — no HPG axis data
Origin
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development
—
—
02Dosage Protocols
Parameter
Liraglutide
Testagen
Standard dose (weight, Saxenda)
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
—
Frequency
Once daily, same time each day
Once daily or alternate days
Titration schedule
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
—
Evidence basis
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Animal mechanistic / in vitro onlyFedoreyeva 2011
Duration
Indefinite for chronic indication
—
Reconstitution
Pre-filled commercial pen (no reconstitution)
Sterile water or bacteriostatic saline
Timing
Any time of day; consistent
—
Typical protocol (anecdotal)
—
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Cycle length
—
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Route
—
Subcutaneous
04Side Effects & Safety
Parameter
Liraglutide
Testagen
GI symptoms
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
—
Pancreatitis risk
Rare; discontinue if suspected
—
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
—
Hypoglycemia
Low risk as monotherapy; elevated with sulfonylureas / insulin
—
Heart rate
Modest ↑ resting HR (~2-3 bpm)
—
Pregnancy / OB
Contraindicated
—
Injection site reactions
—
Erythema, mild irritation (potential)
Systemic effects
—
Unknown — no human safety data
Hormonal impact
—
No published data on testosterone, LH, FSH effects
Long-term safety
—
Unknown — no long-term studies
Absolute Contraindications
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
Testagen
- ·Active testicular malignancy
Relative Contraindications
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
05Administration Protocol
Parameter
Liraglutide
Testagen
1. Reconstitution / device
Commercial pre-filled pen, no reconstitution required.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites.
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Timing
Once daily, same time each day. Take with or without food.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Storage
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Needle
Pen-supplied 32G needle.
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.